Enphys Acquisition Corp. (NYSE:NFYS – Get Rating) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 2,800 shares, a decrease of 20.0% from the February 13th total of 3,500 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 86,300 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of NFYS. Centiva Capital LP acquired a new position in Enphys Acquisition during the second quarter worth about $143,000. Mizuho Securities USA LLC acquired a new position in shares of Enphys Acquisition in the third quarter valued at approximately $214,000. Virtu Financial LLC increased its stake in shares of Enphys Acquisition by 136.5% in the third quarter. Virtu Financial LLC now owns 29,057 shares of the company's stock valued at $283,000 after buying an additional 16,773 shares during the period. First Trust Capital Management L.P. bought a new position in shares of Enphys Acquisition during the 4th quarter worth approximately $478,000. Finally, Bank of Montreal Can bought a new position in shares of Enphys Acquisition during the 2nd quarter worth approximately $1,544,000. Institutional investors and hedge funds own 78.39% of the company's stock.

Enphys Acquisition Trading Down 0.1 %

NFYS traded down $0.01 on Tuesday, hitting $10.17. 47,547 shares of the stock were exchanged, compared to its average volume of 127,581. Enphys Acquisition has a 12 month low of $9.60 and a 12 month high of $10.60. The business has a 50-day moving average of $10.10 and a two-hundred day moving average of $9.93.

Enphys Acquisition Company Profile

(Get Rating)

Enphys Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.

Recommended Stories

• Get a free copy of the StockNews.com research report on Enphys Acquisition (NFYS)
• Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
• GitLab Crashes On Guidance; Analysts Defend
• Healthcare Stocks With at Least 30 Years of Dividend Increases
• Coinbase Pops As SVB Crumbles To Dust
• Airlines Update Guidance, Shares Head For Different Destinations

Receive News & Ratings for Enphys Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enphys Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.